Completed PHASE1 INTERVENTIONAL 1-arm NCT01027182

Comparison of Concentration-time Course of Plasma and Intracellular Raltegravir in Healthy Volunteers

Comparison of Concentration-time Course of Plasma and Intracellular Raltegravir in Healthy Volunteers.

Sponsor: Changi General Hospital

Interventions Raltegravir

Updated 6 times since 2017 Last updated: Mar 18, 2010 Started: Dec 31, 2009 Primary completion: Mar 31, 2010 Completion: Mar 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Human Immunodeficiency Virus and is currently completed. Changi General Hospital leads this study, which shows 6 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jun 2022 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Jun 2022 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Dec 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Changi General Hospital
Merck Sharp & Dohme LLC
National University Hospital, Singapore

Data source: Changi General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Singapore, Singapore